Other formats:
BibTeX
LaTeX
RIS
@article{1802378,
author = {Krejčí, Marta and Pour, Luděk and Adam, Zdeněk and Sandecká, Viera and Štork, Martin and Ševčíková, Sabina and Krejčí, Martin and Knechtová, Zdeňka and Král, Zdeněk},
article_location = {New York},
article_number = {10},
doi = {http://dx.doi.org/10.1007/s00277-021-04594-w},
keywords = {Multiple myeloma; COVID-19; Novel drugs; Hospitalization; Mortality},
language = {eng},
issn = {0939-5555},
journal = {Annals of hematology},
title = {Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience},
url = {https://link.springer.com/article/10.1007%2Fs00277-021-04594-w},
volume = {100},
year = {2021}
}
TY - JOUR
ID - 1802378
AU - Krejčí, Marta - Pour, Luděk - Adam, Zdeněk - Sandecká, Viera - Štork, Martin - Ševčíková, Sabina - Krejčí, Martin - Knechtová, Zdeňka - Král, Zdeněk
PY - 2021
TI - Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience
JF - Annals of hematology
VL - 100
IS - 10
SP - 2541-2546
EP - 2541-2546
PB - Springer Verlag
SN - 09395555
KW - Multiple myeloma
KW - COVID-19
KW - Novel drugs
KW - Hospitalization
KW - Mortality
UR - https://link.springer.com/article/10.1007%2Fs00277-021-04594-w
N2 - Infections are the primary cause of morbidity and mortality in multiple myeloma (MM) patients (pts). The aim of our retrospective analysis was to evaluate incidence and course of COVID-19 infection in a cohort of 351 MM outpatients treated with novel drugs. COVID-19 disease was detected in 50/351 pts (14%); median age was 68 years. Gender, ISS stage, and last treatment lines were as follows: male 32, female 18; ISS-I 19, ISS-II 20, ISS-III 11; daratumumab-based 15, lenalidomide-based 12, bortezomib-based 17, other 6. Positive PCR test at COVID-19 diagnosis was present in all pts; anti-myeloma treatment was interrupted. Hospitalizations for COVID-19 pneumonia were necessary for 28/50 pts (56%), 18/50 pts (36%) in standard unit (SU) 10/50 pts (20%) in intensive care unit (ICU), and 9/50 pts (18%) died. The statistically significant parameters for COVID-19 hospitalization were as follows: responsive versus non-responsive disease (p = 0.027), ECOG performance status 0-2 versus >= 3 (p = 0.014), presence of comorbidities (0-1 versus >= 2, p = 0.043). The statistically significant factors for COVID-19 death were as follows: ECOG 0-2 versus >= 3 (p = 0.001), presence of comorbidities (0-1 versus >= 2, p = 0.007), serious course of COVID-19 disease with ICU hospitalization (SU versus ICU, p = 0.001). None of the other studied risk factors was associated with poor outcome (age, gender, ISS stage, immunoparesis, type of anti-myeloma treatment). Full recovery from COVID-19 infection was observed in 41/50 pts (82%) in median of 32 days. The course of COVID-19 disease in MM pts was mostly moderate or serious with 56% of hospitalizations and 18% of deaths.
ER -
KREJČÍ, Marta, Luděk POUR, Zdeněk ADAM, Viera SANDECKÁ, Martin ŠTORK, Sabina ŠEVČÍKOVÁ, Martin KREJČÍ, Zdeňka KNECHTOVÁ and Zdeněk KRÁL. Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience. \textit{Annals of hematology}. New York: Springer Verlag, 2021, vol.~100, No~10, p.~2541-2546. ISSN~0939-5555. Available from: https://dx.doi.org/10.1007/s00277-021-04594-w.
|
